Cabozantinib is an oral TKI of MET, VEGFRs, and AXL initially tested in a single–arm, phase I study of advanced RCC patients resistant to VEGF and mTOR inhibitors (28) that has now entered the armamentarium of agents for patients with TKI refractory disease. This evidence concerns the gene MTOR and renal cell adenocarcinoma.